We are excited (but not surprised) to announce TScan has been named a Top Place to Work by The Boston Globe for two consecutive years! Interested in joining our mission-focused team with an industry-leading culture? Check out our job openings: https://bit.ly/3GoUGAW #WorkBoston #CellTherapy
关于我们
TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system. TScan Therapeutics was founded in 2018 by a small group of scientists led by Dr. Stephen Elledge (Harvard Medical School/HHMI). TScan is discovering and developing novel TCR-engineered T cell therapies for the treatment of cancer. Our discovery platform is centered around a breakthrough technology that enables the rapid, comprehensive, and genome-wide identification of the peptide antigen targets of T cell receptors. This technology greatly enhances our ability to understand the specific antigens that drive important disease processes, including tumor cell recognition by the immune system, self-reactivity in autoimmune disorders, and acquired immunity in infectious disease. TScan is using the platform in oncology to discover new TCR/target pairs and to rapidly move novel TCRs into clinical development.
- 网站
-
https://www.tscan.com/
TScan Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Waltham，Massachusetts
- 类型
- 上市公司
- 创立
- 2018
- 领域
- TCR-T Cell Therapy
地点
-
主要
获取路线
830 Winter St
US，Massachusetts，Waltham，02451
TScan Therapeutics员工
动态
-
TScan Therapeutics is proud to be named to the 2024 Top Workplaces list for Appreciation, Employee Well-Being, and Professional Development! This recognition is a direct result of the invaluable feedback from #TScanners. These awards reflect our commitment to creating a culture where appreciation, well-being, and professional growth are at the heart of everything we do. A huge thank you to our amazing team for making this achievement possible! #TopWorkplaces #Culture https://lnkd.in/gjVVGcKu
-
-
Today we reported third quarter financial results and provided a corporate update. Read the press release to learn more about our recent accomplishments and upcoming anticipated milestones: https://bit.ly/3Z4LzzD?#CellTherapy #UnleashImmunity #TCells
-
-
Happy #NationalSTEMDay! At #TScan, we know that science, technology, engineering, and math are driving forces behind innovation in biotech. To celebrate and inspire the next generation of STEM talent, we heard from some of our #TScanners on the importance of STEM and what it means to them to be part of this field. #STEMinBiotech
-
-
-
-
-
+2
-
-
Today we announced that preliminary results from the ALLOHA? Phase 1 trial of TSC-100 and TSC-101 in patients with #AML, #ALL, and #MDS will be featured in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7 – 10 in San Diego, CA. Join our virtual KOL event on Tuesday, December 10 at 8:00 a.m. ET where we will discuss the data presented at #ASH24. Learn more: https://bit.ly/3UH9gez #CellTherapy
-
-
This week, we had the incredible opportunity to hear from Emmett Hedblom, Gaenna Rogers, Lori McPartlin, and Elly Todorova in our latest installment of #CareerJourneys! These TScanners shared their unique paths and experiences that led them to #TScan! Every journey is valuable, and it was inspiring to learn from their stories. Thank you all for sharing your insights!
-
-
We’re pleased to be featured in a Nature Biotechnology article highlighting the potential of T cell receptor (TCR)-engineered T cell (TCR-T) therapies?for #SolidTumors. Thank you Nature Portfolio for speaking with our CEO, Gavin MacBeath, PhD, about our approach to provide customized multiplex TCR-T therapies for patients with a variety of #Cancers. Read the article: https://bit.ly/48dW3zH #CellTherapy
-
-
Today we announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6 - 10 in Houston, TX and virtually. Learn more: https://bit.ly/3BFrDK8 #SITC24 #CellTherapy
-
-
Today is #WorldCancerResearchDay. Every day, our team supports #CancerResearch by working to advance potentially life-changing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for patients with #Cancer. Explore our pipeline: https://bit.ly/4bdd4dp #CellTherapy
-
-
What a night! Our annual Charity Casino Night was a huge success in raising over $20,000 for St. Jude Children's Research Hospital - ALSAC. #TScanners and their guests enjoyed an evening full of excitement, games, and a silent auction and raffle baskets with fantastic prizes, all benefitting St. Jude. Thank you to everyone who joined us and contributed to such a meaningful cause! #TScan #UnleashImmunity
-